2. Search Result
Search Result
Results for "

Fatty acid transport protein

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Natural
Products

1

Recombinant Proteins

2

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-116788
    Lipofermata
    Maximum Cited Publications
    8 Publications Verification

    		 Bacterial Infection
    Lipofermata is a fatty acid transport protein 2 (FATP2) inhibitor. Lipofermata shows fatty acid transport inhibition with an IC50 of 4.84 μM in Caco-2 cells. Lipofermata, an analog of spiro-indoline-thadiazole, shows zinc-specific suppression of antibacterial activity. Lipofermata perturbs zinc homeostasis in E. coli K-12 with a MIC of 16 μM .
    Lipofermata
  • HY-CP002
    Bovine Serum Albumin, Carrier Protein

    		Biochemical Assay Reagents Others
    Bovine Serum Albumin (BSA) is a 583 amino acid protein consisting of three homologous full alpha structural domains. BSA is a spherical protein essential for the transport of molecules such as fatty acids, drugs and hormones from the blood. It is used in many biochemical applications as a drug carrier for biologically active compounds. For long-term storage, recombinant protein solution should be diluted further with 0.1% BSA .
    Bovine Serum Albumin, Carrier Protein
  • HY-W020012
    Fluoresterol

    22-NBD Cholesterol

    		 Fluorescent Dye Metabolic Disease
    Fluoresterol (22-NBD Cholesterol) is a cholesterol-specific fluorescent probe with cholesterol-mimicking binding properties. Fluoresterol is ineffective orally and does not cross the blood-brain barrier. Fluoresterol specifically binds to cholesterol transport-related proteins (such as ABCA1 and ABCG1) and is primarily used in cholesterol metabolism research, particularly for the visualization and quantitative analysis of cholesterol absorption, efflux, intracellular transport efficiency, and reverse cholesterol transport (RCT) processes. The commonly used concentration of Fluoresterol in in vitro experiments is 0.1-10 μM, and the commonly used dose in in vivo experiments is 5-20 mg/kg (gavage or intraperitoneal injection), with excitation/emission wavelengths of 472/540 nm. Fluoresterol can be applied to the study of cholesterol metabolism mechanisms related to hyperlipidemia, atherosclerosis, and non-alcoholic fatty liver disease (NAFLD) .
    Fluoresterol
  • HY-N0468
    Rebaudioside D
    1 Publications Verification

    		 FXR Acetyl-CoA Carboxylase Metabolic Disease
    Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D
  • HY-141699
    FATP1-IN-1
    1 Publications Verification

    		 FATP Metabolic Disease
    FATP1-IN-1 (compound 5k) is a fatty acid transport protein 1 (FATP1) inhibitor. FATP1-IN-1 is an inhibition of recombinant human or mouse acyl-CoA synthetase activity of FATP1, with the IC50 values of 0.046 μM or 0.60 μM, respectively .
    FATP1-IN-1
  • HY-141700
    FATP1-IN-2
    2 Publications Verification

    		 FATP Metabolic Disease
    FATP1-IN-2 (compound 12a), an arylpiperazine derivative, is an orally active fatty acid transport protein 1 (FATP1) inhibitor (human IC50=0.43 μM, mouse IC50=0.39 μM) .
    FATP1-IN-2
  • HY-N0468R
    Rebaudioside D (Standard)

    		Reference Standards Acetyl-CoA Carboxylase FXR Metabolic Disease
    Rebaudioside D (Standard) is the analytical standard of Rebaudioside D. This product is intended for research and analytical applications. Rebaudioside D is an orally active sweetener that targets and activates FXR, modulates Acetyl-CoA Carboxylase, and inhibits 3-hydroxy-3-methylglutaryl-CoA reductase. Rebaudioside D regulates bile acid homeostasis and lipid metabolism, reduces the synthesis rates of fatty acids and cholesterol, and exerts multiple effects including anti-adipogenesis, hepatoprotection, anti-steatosis, gut microbiota modulation, enhancement of secondary bile acid metabolism, anti-endotoxin activity, regulation of bile acid transport, and inhibition of bile acid efflux. Rebaudioside D also reduces body weight gain, visceral fat accumulation, hepatic triglyceride and cholesterol accumulation, hepatic lipid peroxidation, and decreases the circulating level of lipopolysaccharide-binding protein. Rebaudioside D additionally enhances the secondary bile acid metabolic pathway of intestinal bacteria, upregulates the gene expression of ileal organic solute transporter α, and downregulates the gene expression of hepatic bile salt export pump. Rebaudioside D does not affect glucose homeostasis, alter total caloric intake or fecal energy excretion, induce weight gain, exacerbate obesity, promote hepatic steatosis, impair brown adipose tissue function, nor change skeletal muscle metabolism-related proteins. Rebaudioside D can be used in diet-induced obesity and obesity-related research .
    Rebaudioside D (Standard)
  • HY-N15885
    12-NBD Stearate

    		Fluorescent Dye FABP Phosphatase Metabolic Disease
    12-NBD Stearate is a fluorescent fatty acid analogue. 12-NBD Stearate binds to fatty acid binding protein (FABP) and sterol carrier protein-2 (SCP-2). Overexpressing sterol carrier protein-2 (SCP-2) 15-kDa isoform enhances 12-NBD Stearate transport. 12-NBD Stearate is a tool for microscopic long chain fatty acids (LCFA) uptake and internalization studies .
    12-NBD Stearate
  • HY-P2832B
    Acyl-coenzyme A Synthetase, Pseudomonas sp.

    		Endogenous Metabolite Metabolic Disease
    Acyl-coenzyme A Synthetase, Pseudomonas sp. (EC 6.2.1.3) belongs to the ligase family and can activate the breakdown of complex fatty acids. Acyl-coenzyme A Synthetase, Pseudomonas sp. (EC 6.2.1.3) catalyzes the production of fatty acyl-CoA in a two-step process via an adenylate intermediate. Acyl-coenzyme A Synthetase, Pseudomonas sp. (EC 6.2.1.3) catalyzes the pre-reaction of fatty acid β-oxidation and can also be incorporated into phospholipids. Acyl-coenzyme A Synthetase, Pseudomonas sp. (EC 6.2.1.3) protein is involved in regulating and promoting the transport of long-chain fatty acids in mammalian cells.
    Acyl-coenzyme A Synthetase, Pseudomonas sp.

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: